Reimbursement in China

Reimbursement for Medical Devices in China
Reimbursement for Pharmaceuticals/Drugs in China

Although China does not have universal healthcare yet, the government's Basic Medical Insurance system covers close to 200 million urban Chinese and is growing quickly. China partially reimburses the cost of many drugs, as well as a few medical devices. To be reimbursed, a drug must be put on China's National Reimbursement Drug List (NRDL). NRDL inclusion can greatly expand the potential market of a drug in China by making it more accessible to middle to lower income consumers.

However, inclusion in the NRDL is difficult. It is theoretically revised every two years, but the scheduled revision timeframe is not always exact. Success usually requires strong support for drug reimbursement among Chinese Key Opinion Leaders (KOLs), whom the government taps to make recommendations. For medical devices, reimbursement is currently limited and will vary according to the province and hospital where the procedure is done.

PBM can devise and implement a reimbursement strategy to obtain optimal pricing for your medical product in China. PBM can help balance optimal pricing issues with time to market.

For more information on reimbursement in China, please see the following PBM publications and/or contact us to discuss your specific needs.

More on China

Get Sourcing/Manufacturing in Asia Consulting

Back to top